Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Amgen, Inc. (NQ: AMGN)
101.50 USD  UNCHANGED
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Amgen, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
RBCC JV Target Amarantus Explores Orphan Drug Designation for MANF
November 26, 2012
from Business Wire News Releases
Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012
November 23, 2012
Five Star Equities Provides Stock Research on Amgen and Regeneron Pharmaceuticals Read More
from Marketwired News Releases
Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
November 20, 2012
from PR Newswire
RBCC: Short R&D Timeline Could Lead to Larger Profits
November 19, 2012
from Business Wire News Releases
RBCC JV Target Amarantus Secures $1.1 Million in Financing
November 15, 2012
from Business Wire News Releases
Critical Alerts For Amgen, Southwestern Energy, AmerisourceBergen, Westport Innovations, and Fusion-io Released By InvestorsObserver
November 14, 2012
from PR Newswire
RBCC Scouts New Biotech Innovations at NIBA Investment Conference
November 14, 2012
from Business Wire News Releases
Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting
November 12, 2012
from PR Newswire
RBCC Joint Venture’s Technology Could Lead to Cancer-Fighting Breakthrough
November 12, 2012
from Business Wire News Releases
RBCC: n3D Technology Advances Cell Research
November 07, 2012
from Business Wire News Releases
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
November 06, 2012
LAPLACE-TIMI 57 Showed AMG 145 Reduced LDL Cholesterol up to 66 Percent in Patients Currently Taking Statins Read More
from PR Newswire
Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia
November 05, 2012
AMG 145 Combination Therapy With Statins Reduced LDL Cholesterol up to 56 Percent Read More
from PR Newswire
Journal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients
November 05, 2012
AMG 145 Reduced LDL Cholesterol by up to 51 Percent in a Difficult-to-Treat Population Read More
from PR Newswire
Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial Published In The New England Journal Of Medicine
November 03, 2012
Study Results Simultaneously Presented at American Society of Nephrology's Kidney Week Read More
from PR Newswire
Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
November 02, 2012
from PR Newswire
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012
November 01, 2012
from PR Newswire
RBCC: Mobile Technology May Help Reduce Athletes’ Risk of Brain Injury
October 31, 2012
from Business Wire News Releases
RBCC: Alzheimer’s Epidemic Draws $100 Million in Research
October 24, 2012
from Business Wire News Releases
Amgen's Third Quarter 2012 Revenues Increased 10 Percent To $4.3 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $1.67
October 23, 2012
2012 Total Revenues and Adjusted EPS Guidance Ranges Increased to $17.2-$17.3 Billion and $6.50-$6.60 Read More
from PR Newswire
Traders Look to New Levels Ahead - Research & Analysis on Amgen Inc. and Glaxosmithkline Plc
October 23, 2012
from Marketwired News Releases
Amgen Announces Webcast of 2012 Third Quarter Financial Results
October 18, 2012
from PR Newswire
RBCC: Could Stem Cells Be Key to Promising Autism Therapy?
October 16, 2012
from Business Wire News Releases
Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial
October 14, 2012
Prolia Open-Label Extension Trial Showed Continued Increases in Bone Mineral Density and Low Fracture Incidence Over Six Years Read More
from PR Newswire
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer
October 12, 2012
from PR Newswire
Amgen Announces 2012 Fourth Quarter Dividend
October 11, 2012
from PR Newswire
RBCC: Nobel Prize Could Bring Big Investments in Stem Cell Research
October 11, 2012
from Business Wire News Releases
RBCC: NASA Bioreactor Could Speed Parkinson’s Research
October 04, 2012
from Business Wire News Releases
RBCC Looks to China for Stem Cell Research
October 03, 2012
from Business Wire News Releases
RBCC: Could Stem Cells Hold the Key to Treating Traumatic Brain Injuries?
October 01, 2012
from Business Wire News Releases
RBCC: Stem Cell Market Poised for Billion-Dollar Growth
September 27, 2012
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here